Skip to main content

Table 3 Prognostic value of IGF1R intensity in ER-negative and ER-positive patients in Cohort I (a) and II (b), respectively

From: Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer

a)
Cohort I   DDFS univariable DDFS multivariablea
   N HR 95% CI p-value N HR 95% CI p-value
Cytoplasm All patients 264 0.70 0.52-0.94 0.016 220 0.80 0.57-1.1 0.18
  ER+ 174 1.2 0.76-2.0 0.40 152 1.21 0.72-2.0 0.46
  ER- 80 0.62 0.40-0.96 0.033 68 0.49 0.29-0.82 0.007
Membrane All patients 264 0.58 0.39-0.86 0.007 220 0.71 0.46-1.1 0.13
  ER+ 174 0.89 0.54-1.5 0.63 152 0.91 0.54-1.5 0.72
  ER- 80 0.44 0.20-0.97 0.041 68 0.32 0.13-0.79 0.014
b)
Cohort II   DDFS univariable DDFS multivariable b
   N HR 95% CI p-value N HR 95% CI p-value
Cytoplasm All patients 206 0.87 0.52-1.5 0.61 179 1.0 0.59-1.8 0.91
  ER+ 139 1.1 0.48-2.5 0.83 122 1.2 0.53-2.9 0.62
  ER- 67 0.81 0.42-1.56 0.53 57 0.71 0.32-1.6 0.39
Membrane All patients 206 0.87 0.53-1.4 0.57 179 1.03 0.57-1.9 0.92
  ER+ 139 1.3 0.64-2.5 0.51 122 1.2 0.59-2.5 0.60
  ER- 67 0.72 0.34-1.5 0.37 57 0.84 0.31-2.3 0.74
  1. aMultivariable Cox-regression for IGF1R intensity adjusted for node positivity, tumor size, HER2, Ki67, menopausal status and, among all patients, ER status.
  2. bMultivariable Cox-regression for IGF1R intensity adjusted for age, tumor size, HER2, Ki67 and, among all patients, ER status.